Organic Active Ingredients TRIZ Cases

Selective small molecule inhibitors target MLH1 and PMS2 proteins to restore genome stability and enhance immune activation in MMR-deficient cancers.

Column chromatography and fumarate salt formation remove impurities exceeding 0.5% and residual solvents above 500 ppm from 5-MeO-DMT.

A pharmaceutical composition merges benzoheterocyclic compounds with androgen receptor pathway modulators to inhibit prostate cancer cell proliferation.

Specific NEK7 inhibitor compounds target kinase activity to address unmet therapeutic needs.

Administering beneficial bacteria like Roseburia and Faecalibacterium prausnitzii to boost immune surveillance and improve cancer treatment outcomes.

A therapeutic formula combines plant and animal amino acids with prebiotics to enhance nutrient absorption in children.

A phenylpropanoid compound from locust bean pods inhibits melanin production and scavenges free radicals.

A 3-carbamoyl-1-methylpyridinium nitrite salt acts as a bioactive nitric oxide donor and enhances prostacyclin secretion.

Determining stromal MCT4 protein levels in tumor tissue samples to classify cancer patients into distinct response groups.

Combining pioglitazone with mesenchymal stromal cells reduces neuroinflammatory markers in acute respiratory distress syndrome.

Upregulating lncRNA DCRT via recombinant vectors reduces myocardial cell area and addresses mitochondrial dysfunction in dilated cardiomyopathy.

Optimizing pemafibrate concentration within 0.017 to 4.2 mass % resolves content uniformity contradictions, ensuring consistent efficacy and safety.

Liposome nanocarriers target bone marrow to protect against radiation while minimizing tumor exposure.

A phosphopeptide inhibitor disrupts the physical interaction between TrkB and PLCγ1 to reduce seizure activity.

Oral glyceryl tris(3-hydroxybutyrate) esters achieve therapeutic ketone body levels while avoiding hyperglycemia associated with traumatic brain injury.

Anti-IL-6 antibodies bind human IL-6 to reduce C-reactive protein and increase serum albumin, improving patient survivability despite monitoring complexity.

A bismuth sequestering agent captures released 213Bi daughter nuclides from actinium decay chains.

Ophthalmic compositions deliver antiviral agents to the ocular surface, reducing systemic side effects while blocking viral entry.

Segmenting drug attachment from encapsulation resolves the trade-off between multi-drug capacity and precise composition control.

Optimized Formula I compounds deliver potent p70 S6 kinase inhibition, addressing the lack of effective inhibitors for treating multiple cancer types.

A ready-to-use norepinephrine IV solution formulated in flexible plastic bags maintains isotonicity and pH stability at room temperature.

pH-responsive polymer coatings on lipid nanoparticles enable precise tumor accumulation and cellular uptake.

Tartaric acid analogs bind phosphatidylserine to reverse T-cell signaling arrest and overcome tumor resistance in solid cancers.

Administering phenylbutyrate to inclusion body myositis patients while measuring mitochondrial membrane potential changes using fluorescent trackers.

Extraction of viral genomes from virus-like particles enables targeted gene downregulation without genomic integration risks.

Pyridyl substituted indole compounds resolve the contradiction between therapeutic effectiveness and compound stability by inhibiting TLR7/8/9 signaling.

Sn-1 monoacylglycerols facilitate nutrient absorption despite lipase inhibition, preventing deficiencies from weight loss treatments.

Arylthiadiazole compounds inhibit TAU misfolding and aggregation, addressing the root cause of neuronal damage in tauopathies.

Combining lixisenatide with basal insulin reduces body weight and HbA1c levels, resolving the contradiction between glycemic control and weight gain.

Combined parenteral and oral levodopa administration reduces motor fluctuations and dyskinesia in Parkinson's disease treatment.

A pyrrolidinone-piperazine compound inhibits monoacylglycerol lipase to elevate 2-AG levels.

Bridged cyclic amine derivative inhibits menin-MLL fusion protein binding, resolving the trade-off between therapeutic efficacy and pharmacokinetic properties.

CDP-ribitol serves as a sugar donor to restore abnormal glycosylation in muscular dystrophies by incorporating ribitol-phosphate into dystroglycan.

A stable aqueous injectable solution combines human insulin A21G with an amylin analogue at pH 3.5 to 4.4.

Segmented adsorbent isolates antagonist to deter tampering while maintaining controlled active agent release.

Encapsulated solubilized estradiol eliminates the need for vaginal secretions to activate treatment, ensuring consistent drug release and reducing discharge.

Converting the free base to a hydrochloride salt resolves thermodynamic stability and purity bottlenecks while maintaining therapeutic efficacy.

Iron(III)-beta-ketoamide complexes enable direct intestinal uptake of ferric iron, preventing reactive oxygen species formation and oxidative stress.

Ion-exchange resin with divalent cations balances nicotine stability against release speed.

Novel BLT2 inhibitor compounds with modified molecular structures resolve metabolic instability in anti-inflammatory treatments.

A medical device coating layer containing a surfactant additive facilitates rapid and uniform drug elution from the exterior surface.

Poloxamer 188 and lactose maintain peptide solubility and stability, preventing aggregation to enable effective parenteral delivery.

Substituted pyrazolo[1,5-a]pyrimidine compounds inhibit protein kinases through specific structural scaffolds.

Combining SUV39H1 inhibition with immune checkpoint modulators enhances anti-tumor efficacy while reducing collateral toxicity to healthy tissues.

Formula I heterocyclic compounds target the GPR119 receptor to treat obesity and diabetes while reducing adverse effects associated with existing therapies.

PCR, FISH, and sequencing detect FGFR3-TACC3 fusions in cervical tissue to identify patients eligible for targeted inhibitor therapy.

Formula I pyridinyl quinolinone derivatives inhibit mutant IDH enzymes, reducing 2-hydroxyglutarate accumulation in proliferative cancers.